RSV Immunogenicity Study in the Elderly (RISE)

Respiratory syncytial virus (RSV) is a common cause of respiratory tract infections leading to hospitalizations in infants and in elderly. Arexvy is an approved vaccine for the prevention of RSV infection, however, data on its efficacy in individuals aged 80 years and older remain limited. This study aims to evaluate potential differences in immune responses to Arexvy vaccination between adults aged ≥80 years and those aged 60-65 years.

NCT Number	NCT07203365
Lead Sponsor	Karin Karin Loré Collaborators: Karolinska Institutet
Conditions	RSV Immunisation
Enrollment	65 participants
Start Date	2025-08-25
Primary Completion	2027-05-31 (estimated)
Study Completion	2029-05-31 (estimated)
Updated on ClinicalTrials.gov	2025-10-02